Literature DB >> 10373446

Daunomycin-induced unfolding and aggregation of chromatin.

A Rabbani1, M Iskandar, J Ausió.   

Abstract

Using equilibrium dialysis and sedimentation velocity analysis, we have characterized the binding of the anti-tumor drug daunomycin to chicken erythrocyte chromatin before and after depletion of linker histones and to its constitutive DNA under several ionic strengths (5, 25, and 75 mM NaCl). The equilibrium dialysis experiments reveal that the drug binds cooperatively to both the chromatin fractions and to the DNA counterpart within the range of ionic strength used in this study. A significant decrease in the binding affinity was observed at 75 mM NaCl. At any given salt concentration, daunomycin exhibits higher binding affinity for DNA than for linker histone-depleted chromatin or chromatin (in decreasing order). Binding of daunomycin to DNA does not significantly affect the sedimentation coefficient of the molecule. This is in contrast to binding to chromatin and to its linker histone-depleted counterpart. In these instances, preferential binding of the drug to the linker DNA regions induces an unfolding of the chromatin fiber that is followed by aggregation, presumably because of histone-DNA interfiber interactions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10373446     DOI: 10.1074/jbc.274.26.18401

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

Review 1.  A revisit of the mode of interaction of small transcription inhibitors with genomic DNA.

Authors:  Dipak Dasgupta; Parijat Majumder; Amrita Banerjee
Journal:  J Biosci       Date:  2012-07       Impact factor: 1.826

2.  The role of the VPS4A-exosome pathway in the intrinsic egress route of a DNA-binding anticancer drug.

Authors:  Vivien Y Chen; Maria M Posada; Levi L Blazer; Tong Zhao; Gus R Rosania
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

3.  Mechanism of the interaction of plant alkaloid vincristine with DNA and chromatin: spectroscopic study.

Authors:  Azadeh Mohammadgholi; Azra Rabbani-Chadegani; Sodabeh Fallah
Journal:  DNA Cell Biol       Date:  2013-04-16       Impact factor: 3.311

4.  Role of Chromatin Damage and Chromatin Trapping of FACT in Mediating the Anticancer Cytotoxicity of DNA-Binding Small-Molecule Drugs.

Authors:  Elimelech Nesher; Alfiya Safina; Ieman Aljahdali; Scott Portwood; Eunice S Wang; Igor Koman; Jianmin Wang; Katerina V Gurova
Journal:  Cancer Res       Date:  2018-01-16       Impact factor: 12.701

5.  The effect of mitoxantrone as an anticancer drug on hepatocytes nuclei and chromatin: Selective release of histone proteins.

Authors:  Zahra Hajihassan; Azra Rabbani-Chadegani
Journal:  Indian J Pharmacol       Date:  2011-04       Impact factor: 1.200

6.  Studies on the binding affinity of anticancer drug mitoxantrone to chromatin, DNA and histone proteins.

Authors:  Zahra Hajihassan; Azra Rabbani-Chadegani
Journal:  J Biomed Sci       Date:  2009-03-11       Impact factor: 8.410

7.  Interaction of anthracyclines with iron responsive element mRNAs.

Authors:  Joshua C Canzoneri; Adegboyega K Oyelere
Journal:  Nucleic Acids Res       Date:  2008-10-25       Impact factor: 16.971

8.  Nucleosome stability measured in situ by automated quantitative imaging.

Authors:  László Imre; Zoltán Simándi; Attila Horváth; György Fenyőfalvi; Péter Nánási; Erfaneh Firouzi Niaki; Éva Hegedüs; Zsolt Bacsó; Urbain Weyemi; Rebekka Mauser; Juan Ausio; Albert Jeltsch; William Bonner; László Nagy; Hiroshi Kimura; Gábor Szabó
Journal:  Sci Rep       Date:  2017-10-06       Impact factor: 4.379

Review 9.  Chromatin as a target for the DNA-binding anticancer drugs.

Authors:  Parijat Majumder; Suman K Pradhan; Pukhrambam Grihanjali Devi; Sudipta Pal; Dipak Dasgupta
Journal:  Subcell Biochem       Date:  2007

10.  Doxorubicin induces large-scale and differential H2A and H2B redistribution in live cells.

Authors:  Péter Nánási; László Imre; Erfaneh Firouzi Niaki; Rosevalentine Bosire; Gábor Mocsár; Anett Türk-Mázló; Juan Ausio; Gábor Szabó
Journal:  PLoS One       Date:  2020-04-16       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.